Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
It’s a universally familiar phrase. Ask any English-speaking adult or child, and they will recognize the label “goody two-shoes” as derogatory shorthand for an insufferable prude—but few remember how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results